Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients
Yıl: 2021 Cilt: 59 Sayı: 3 Sayfa Aralığı: 300 - 303 Metin Dili: İngilizce İndeks Tarihi: 31-01-2022
Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients
Öz: Objective: This study evaluates the vitamin D results inpatients diagnosed with vitamin D deficiency and used the oral vitamin D in capsule form twice a week for 2x20000UI during eight weeks (D-Colefor 14 capsules). Material and Methods: Patients who were found to have vitamin D deficiency and whose vitamin D level was 20 ng/dl and below, who used oral vitamin D (D-Colefor capsule) 40000 IU per week (2X20000 IU for two days) for eight weeks and whose vitamin D measurement was made at the end of eight weeks were included in the study. Our study was conducted retrospectively bys scanning patient files. We planned to investigate the treatment results by determining the percentage of patients whose vitamin D level exceeded 30 ng/dl, which was considered sufficient, after eight weeks. Results: It was determined that the use of the capsule form of oral vitamin D twice a week for eight weeks for 2x20000 IU increased serum vitamin D levels of 58.8% of the patients to the adequate dose of 30 ng/dl and above.
Anahtar Kelime: D-Colefor (25-OH Vitamin D) Kullanmış Hastalarda Etkinlik ve Güvenliğinin Değerlendirilmesi
Öz: Amaç: D vitaminin eksikliği tanısı alan hastalarda, kullanıma giren kapsül formundaki oral D vitamini preparatını haftada iki gün 2x20000 UI 8 hafta (D-Colefor 14 kapsül) kullanmış hastaların D vitamini sonuçlarının değerlendirilmesi. Materyal ve Metod: D vitamin eksikliği tespit edilmiş olup D vitamin düzeyi 20 ng/dl ve altında olan oral D vitamini ( D-Colefor kapsül) tedavisini haftada 40000 IU(iki gün 2X20000 IU) 8 hafta kullanmış olan ve 8 hafta bitiminde D vitamin ölçümü yapılmış olan hastalar çalışmaya alınmıştır. Çalışmamız retrospektif olarak hasta dosyaları taranarak yapılmıştır. Sekiz hafta sonunda D vitamin düzeyinin yeterli olarak kabul edilen 30 ng/dl üzerine çıkan hasta sayılarının oranını belirleyerek tedavi sonuçlarını araştırmayı planladık. Sonuç: Oral D vitamininin kapsül formunun 8 hafta boyunca hafta da iki doz 2x20000 IU kullanımının serum D vitamin düzeylerini hastaların %58.8 ‘de yeterli doz olan 30 ng/dl ve üzerine yükselttiği saptanmıştır
Anahtar Kelime: Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
- 1.Türkiye Endokrinoloji ve Metabolizma Derneği, Osteoporoz ve Metabolik Kemik Hastalıkları Tanı ve Tedavi Klavuzu, 2019.
- 2.Holick MF. Vitamin D deficiency. N Engl J Med2007;357:266–81
- 3.Heath KM, Elovic EP. Vitamin D deficiency: ımplications in therehabilitationsetting. Am J PhysMedRehabil, 2006;85:916-923.
- 4.Whayne TF. Vitamin D. popular cardiovascularsupplement but benefitmust be evaluated. International Journal of Angiology, 2011;20:63-71.
- 5.Öngen B, Kabaroğlu C, Parıldar Z. D vitamini’nin biyokimyasal ve laboratuvar değerlendirmesi. Türk Klinik Biyokimya Dergisi. 2008; 6: 23- 31.
- 6.Ataş A, Çakmak A, Soran M. D vitamini metabolizması ve Rikets hastalığı. Bakırköy Tıp Dergisi. 2008; 4:1-7.
- 7.Brannon PM, Yetley EA, Bailey RL, Picciano MF. Overview of the conference “Vitamin D andhealth in the 21st century: an update”. Am J ClinNutr. 2008; 88:483-90.
- 8.Mosekilde L. Vitamin D and theelderly. Clin Endocrinol (Oxf). 2005; 62:265-81.
- 9.Tellioğlu A, Başaran S. Güncel bilgiler ışığında vitamin D. ArchivesMedicalReviewJournal. 2013; 22(2):259-271.
- 10.Özçelik DÇ, Koçer H, Kasım İ, Şencan İ, Kahveci R, Özkara A. D vitamini. TurkishMedicalJournal. 2012;6(2): 61-67.
- 11.İyidir ÖT, Altınova AE. Vitamin D ve diabetes. Mellitus Türk Jem. 2012; 16: 89-94
- 12.The ABC of vitamin D a primerforphysicians. Susie Langley. 2007; 43: 23-24
- 13.Brown EM, Gamba G, Riccardl D, et al. Cloningandcharacterization of an extracellularCa-sensingreceptorfrombovineparathyroid. Nature 1993.
- 14.Li YC. Vitamin D regulation of the renin-angiotensinsystem. J Cell Biochem 2003; 88: 327-331.
- 15.Wu S, Sun J. Vitamin D, vitamin D receptor, andmacroautophagy in inflammationandinfection. DiscovMed 2011; 11:325-35.
- 16.Heaney RP, Dowell MS, Hale CA, et al. Calciumabsorptionvarieswithinthereferencerangefor serum 25- hydroxyvitamin D. J AmCollNutr2003;22:142-6.
- 17.Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D formültiplehealthoutcomes. Am J ClinNutr 2006; 84:18-28.
- 18.Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, andprevention of Vitamin D deficiency: an endocrinesocietyclinicalpracticeguideline. J ClinEndocrinMetab 2011; 96:1911-30.
- 19.Ish-Shalom S, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R. Comparison of daily, weekly, andmonthly vitamin D3 in ethanoldosingprotocolsfortwomonths in elderlyhipfracturepatients. J ClinEndocrinolMetab 2008; 93:3430-3435.
- 20.M. Sayıner, G. Arslan, Ş. Temizkan, T. Karabayraktar, M. Sargın. Different vitamin d replacementoptions. Turk J EndocrinolMetab. 2016; 20:6-9.
- 21.Mastaglia SR, Mautalen CA, Parisi MS, Oliveri B. Vitamin D2 doserequiredtorapidlyincrease 25OHD levels in osteoporoticwomen. Eur J ClinNutr 2006; 60:681-687.
- 22.Chel V, Wijnhoven HA, Smit JH, Ooms M, Lips P. Efficacy of differentdosesand time intervals of oral vitamin D supplementationwithorwithoutcalcium in elderlynursinghomeresidents. OsteoporosInt2008;19:663-671.
| APA | SARIAKÇALI B, Duman G, TUNAHAN H (2021). Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients. , 300 - 303. |
| Chicago | SARIAKÇALI BARIS,Duman Gülhan,TUNAHAN HASAN Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients. (2021): 300 - 303. |
| MLA | SARIAKÇALI BARIS,Duman Gülhan,TUNAHAN HASAN Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients. , 2021, ss.300 - 303. |
| AMA | SARIAKÇALI B,Duman G,TUNAHAN H Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients. . 2021; 300 - 303. |
| Vancouver | SARIAKÇALI B,Duman G,TUNAHAN H Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients. . 2021; 300 - 303. |
| IEEE | SARIAKÇALI B,Duman G,TUNAHAN H "Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients." , ss.300 - 303, 2021. |
| ISNAD | SARIAKÇALI, BARIS vd. "Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients". (2021), 300-303. |
| APA | SARIAKÇALI B, Duman G, TUNAHAN H (2021). Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients. Ege Klinikleri Tıp Dergisi, 59(3), 300 - 303. |
| Chicago | SARIAKÇALI BARIS,Duman Gülhan,TUNAHAN HASAN Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients. Ege Klinikleri Tıp Dergisi 59, no.3 (2021): 300 - 303. |
| MLA | SARIAKÇALI BARIS,Duman Gülhan,TUNAHAN HASAN Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients. Ege Klinikleri Tıp Dergisi, vol.59, no.3, 2021, ss.300 - 303. |
| AMA | SARIAKÇALI B,Duman G,TUNAHAN H Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients. Ege Klinikleri Tıp Dergisi. 2021; 59(3): 300 - 303. |
| Vancouver | SARIAKÇALI B,Duman G,TUNAHAN H Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients. Ege Klinikleri Tıp Dergisi. 2021; 59(3): 300 - 303. |
| IEEE | SARIAKÇALI B,Duman G,TUNAHAN H "Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients." Ege Klinikleri Tıp Dergisi, 59, ss.300 - 303, 2021. |
| ISNAD | SARIAKÇALI, BARIS vd. "Evaluation of the Efficacy and Safety of D-Colefor (25-OH Vitamin D) Patients". Ege Klinikleri Tıp Dergisi 59/3 (2021), 300-303. |
